Pan-NR agonists, such as RGX-202, activate PPARα, PPARγ, and PPARδ, leading to improvements in lipid metabolism, insulin sensitivity, and fatty acid oxidation, with potential applications for metabolic syndrome, dyslipidemia, and CVD [247]. The gene discussed is PPARA; the disease is metabolic syndrome.